Two products in this catalogue come from the thymus, and they could hardly be less alike as research materials. Thymosin alpha-1 is a single, fully defined 28-residue peptide with an approved medicine built on it and decades of clinical literature. Thymalin is a polypeptide fraction extracted from bovine thymus, with no single defining sequence at all. Treating them as interchangeable — which a lot of writing does — is the main error worth correcting.
Thymosin Alpha-1: A Defined Molecule
Thymosin alpha-1 is an N-terminally acetylated 28-amino-acid peptide, Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, with a molecular weight of 3108.31 g/mol. It was originally isolated from thymosin fraction 5, a crude thymic extract, and then sequenced and synthesised, which is precisely the step that separates it from thymalin.
Its proposed activity is immunomodulatory rather than immunostimulatory: it is studied for effects on T-cell maturation and on dendritic-cell signalling through Toll-like receptors, which is to say it is described as adjusting an immune response rather than simply amplifying one. It is marketed as a prescription medicine under the name Zadaxin in a number of countries, with approvals centred on hepatitis B and C and on use as a vaccine adjuvant. It is not FDA-approved in the United States.
Thymalin: A Fraction, Not a Molecule
Thymalin is a low-molecular-weight polypeptide complex isolated from bovine thymus, typically described as the 1–10 kDa fraction. That phrasing is doing a lot of work: a fraction is defined by the process used to obtain it, not by a structure. There is no sequence, no single molecular weight, and no formula, because it is a mixture whose exact composition depends on the source tissue and the extraction method.
It belongs to the Russian peptide-bioregulator tradition developed from the 1970s onward, and most of its literature is Russian-language, older, and generally small and unblinded by current standards. That is a statement about the evidence, not a dismissal of the compound, but a researcher should know which kind of evidence they are reading before they cite it.
Why Defined Versus Undefined Matters
The practical consequence shows up on the certificate of analysis, and it is the single most important thing to understand before buying either one.
- For thymosin alpha-1: identity is confirmable. Mass spectrometry should return 3108.31 g/mol for the acetylated 28-mer, and HPLC gives a meaningful purity figure against that single expected peak.
- For thymalin: there is no single expected mass, so "purity" has no clean definition. A percentage on a thymic fraction cannot mean what the same number means on a synthetic peptide, and a certificate that presents it as though it does is misleading by construction.
Anyone comparing the two on price per milligram is therefore comparing different categories of thing. How to read a certificate of analysis covers which fields carry real information, and what HPLC purity testing actually verifies covers the limits of the purity number itself.
What the Published Evidence Supports
For thymosin alpha-1 the evidence base is substantial and genuinely clinical: controlled trials in chronic hepatitis B, adjuvant use alongside vaccination in populations with reduced responses, and a body of sepsis literature including randomised work reported from Chinese centres. Reported tolerability across that literature is good, with local injection-site reactions the most common finding.
For thymalin the position is different. The literature exists but is dominated by small studies, much of it from a single research tradition, and it has not been replicated in the large multicentre trials that would let anyone speak about it with the same confidence. Honest reading of that body is that it is preliminary.
A defined synthetic peptide with randomised clinical data and an extracted tissue fraction with small, largely unreplicated studies are not equivalent inputs to a research question, regardless of a shared organ of origin.
Handling
Both are lyophilised and both are hygroscopic, so the general handling in research peptide storage, shipping and handling applies. Thymosin alpha-1 carries the usual caution for an acetylated peptide, in that the N-terminal modification is part of the identity and a certificate confirming only a purity percentage does not demonstrate that the acetyl group is present.
References & primary sources
Note the asymmetry in the sources below: it reflects a real asymmetry in the two evidence bases rather than a selection choice.
- Goldstein AL, Goldstein AL. (2009) From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion on Biological Therapy 9:593-608.
- Garaci E, Pica F, Rasi G, Favalli C. (2000) Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopharmacology 22:1067-1076.
- Wu J, Zhou L, Liu J, et al. (2013) The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicentre, single-blind, randomised and controlled trial. Critical Care 17:R8.
- Khavinson VK. (2002) Peptides and ageing. Neuroendocrinology Letters 23 Suppl 3:11-144.
- Camerini R, Garaci E. (2015) Historical review of thymosin alpha 1 in infectious diseases. Expert Opinion on Biological Therapy 15 Suppl 1:S117-127.
Questions and answers
What is thymosin alpha-1?
A fully defined, N-terminally acetylated 28-amino-acid peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, 3108.31 g/mol) originally isolated from thymic extract and now made synthetically. It is studied as an immunomodulator affecting T-cell maturation and dendritic-cell signalling.
What is thymalin, and how is it different?
Thymalin is a low-molecular-weight polypeptide fraction extracted from bovine thymus, usually described as the 1-10 kDa fraction. It is defined by the extraction process rather than by a structure, so it has no single sequence or molecular weight. Thymosin alpha-1 is one defined molecule; thymalin is a mixture.
Can a certificate of analysis report purity for thymalin?
Not in the way it can for a synthetic peptide. Purity describes a chromatographic peak measured against a single expected structure, and a thymic fraction has no single expected mass. A purity percentage presented on a fraction does not carry the same meaning and should not be read as though it does.
Is thymosin alpha-1 an approved medicine?
It is approved and marketed in a number of countries under the name Zadaxin, with approvals centred on hepatitis B and C and on vaccine adjuvant use. It is not FDA-approved in the United States. Material supplied for laboratory research is not a medicine and is not supplied for any therapeutic use.
Why is the evidence base so different between the two?
Thymosin alpha-1 has randomised controlled trials including multicentre sepsis work. Thymalin's literature is largely Russian-language, older, and composed of small studies that have not been replicated in large multicentre trials. Both are literature, but they are not equivalent grades of it.